Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABUS NASDAQ:AMAG NASDAQ:ARCT NASDAQ:AVDL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABUSArbutus Biopharma$4.46-9.0%$3.52$2.70▼$5.10$854.98M1.011.52 million shs1.69 million shsAMAGAMAG Pharmaceuticals$13.75$13.74$4.41▼$13.80$477.47M0.89950,664 shsN/AARCTArcturus Therapeutics$17.32-4.0%$15.38$8.04▼$25.88$470.33M2.39499,183 shs644,225 shsAVDLAvadel Pharmaceuticals$15.40-2.9%$12.67$6.38▼$16.66$1.50B1.581.41 million shs1.46 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABUSArbutus Biopharma0.00%+6.19%+32.34%+24.58%-0.22%AMAGAMAG Pharmaceuticals0.00%0.00%0.00%0.00%0.00%ARCTArcturus Therapeutics0.00%-2.97%-11.09%+34.58%-16.53%AVDLAvadel Pharmaceuticals0.00%-2.28%+12.49%+62.11%+12.41%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABUSArbutus Biopharma$4.46-9.0%$3.52$2.70▼$5.10$854.98M1.011.52 million shs1.69 million shsAMAGAMAG Pharmaceuticals$13.75$13.74$4.41▼$13.80$477.47M0.89950,664 shsN/AARCTArcturus Therapeutics$17.32-4.0%$15.38$8.04▼$25.88$470.33M2.39499,183 shs644,225 shsAVDLAvadel Pharmaceuticals$15.40-2.9%$12.67$6.38▼$16.66$1.50B1.581.41 million shs1.46 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABUSArbutus Biopharma0.00%+6.19%+32.34%+24.58%-0.22%AMAGAMAG Pharmaceuticals0.00%0.00%0.00%0.00%0.00%ARCTArcturus Therapeutics0.00%-2.97%-11.09%+34.58%-16.53%AVDLAvadel Pharmaceuticals0.00%-2.28%+12.49%+62.11%+12.41%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABUSArbutus Biopharma 3.00Buy$5.0012.11% UpsideAMAGAMAG Pharmaceuticals 0.00N/AN/AN/AARCTArcturus Therapeutics 3.00Buy$50.57191.98% UpsideAVDLAvadel Pharmaceuticals 3.11Buy$20.8635.44% UpsideCurrent Analyst Ratings BreakdownLatest AVDL, AMAG, ARCT, and ABUS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/5/2025AVDLAvadel PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$24.00 ➝ $36.009/4/2025ARCTArcturus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$60.009/3/2025AVDLAvadel PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold9/3/2025AVDLAvadel PharmaceuticalsLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy9/2/2025AVDLAvadel PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageEqual Weight$16.008/22/2025ARCTArcturus TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$63.00 ➝ $54.008/21/2025AVDLAvadel PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$13.00 ➝ $20.008/12/2025ARCTArcturus TherapeuticsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$47.00 ➝ $49.008/12/2025ARCTArcturus TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$45.00 ➝ $42.008/11/2025ABUSArbutus BiopharmaChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.008/8/2025AVDLAvadel PharmaceuticalsDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABUSArbutus Biopharma$6.17M138.57N/AN/A$0.51 per share8.75AMAGAMAG Pharmaceuticals$327.75M1.46N/AN/A$7.37 per share1.87ARCTArcturus Therapeutics$109.80M4.28N/AN/A$8.90 per share1.95AVDLAvadel Pharmaceuticals$221.08M6.76N/AN/A$0.77 per share20.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABUSArbutus Biopharma-$69.92M-$0.29N/AN/AN/A-352.24%-59.28%-44.11%11/5/2025 (Estimated)AMAGAMAG Pharmaceuticals-$466.46M-$6.88N/A76.39N/A-74.93%-16.92%-5.96%N/AARCTArcturus Therapeutics-$80.94M-$2.23N/AN/AN/A-49.26%-24.87%-17.75%11/6/2025 (Estimated)AVDLAvadel Pharmaceuticals-$48.83M-$0.03N/A256.67N/A-1.32%-3.73%-1.73%11/11/2025 (Estimated)Latest AVDL, AMAG, ARCT, and ABUS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025ARCTArcturus Therapeutics-$1.11-$0.34+$0.77-$0.34$17.64 million$28.30 million8/7/2025Q2 2025AVDLAvadel Pharmaceuticals$0.02$0.10+$0.08$0.10$60.28 million$68.13 million8/6/2025Q2 2025ABUSArbutus Biopharma-$0.02$0.01+$0.03$0.01$2.21 million$10.74 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABUSArbutus BiopharmaN/AN/AN/AN/AN/AAMAGAMAG PharmaceuticalsN/AN/AN/AN/AN/AARCTArcturus Therapeutics$0.714.13%N/AN/A N/AAVDLAvadel PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABUSArbutus BiopharmaN/A20.5320.53AMAGAMAG Pharmaceuticals1.131.751.45ARCTArcturus TherapeuticsN/A5.905.90AVDLAvadel PharmaceuticalsN/A2.792.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABUSArbutus Biopharma43.79%AMAGAMAG PharmaceuticalsN/AARCTArcturus Therapeutics94.54%AVDLAvadel Pharmaceuticals69.19%Insider OwnershipCompanyInsider OwnershipABUSArbutus Biopharma20.30%AMAGAMAG Pharmaceuticals12.73%ARCTArcturus Therapeutics16.60%AVDLAvadel Pharmaceuticals5.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABUSArbutus Biopharma90191.70 million152.78 millionOptionableAMAGAMAG Pharmaceuticals44034.73 millionN/AOptionableARCTArcturus Therapeutics18027.16 million23.00 millionOptionableAVDLAvadel Pharmaceuticals7097.10 million92.05 millionOptionableAVDL, AMAG, ARCT, and ABUS HeadlinesRecent News About These CompaniesWoodline Partners LP Buys 395,040 Shares of Avadel Pharmaceuticals PLC. $AVDL2 hours ago | marketbeat.comAvadel: LUMRYZ Momentum And Pipeline Expansion Support Buy RatingSeptember 12 at 4:02 AM | seekingalpha.comAvadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)September 10, 2025 | globenewswire.comCubist Systematic Strategies LLC Buys Shares of 150,451 Avadel Pharmaceuticals PLC. $AVDLSeptember 10, 2025 | marketbeat.comAvadel Pharmaceuticals Plc (AVDL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)September 9, 2025 | seekingalpha.comAvadel Pharmaceuticals PLC. $AVDL is Two Seas Capital LP's 6th Largest PositionSeptember 9, 2025 | marketbeat.comTrexquant Investment LP Invests $1.01 Million in Avadel Pharmaceuticals PLC. $AVDLSeptember 9, 2025 | marketbeat.comHC Wainwright Has Positive Outlook for AVDL Q1 EarningsSeptember 9, 2025 | marketbeat.comHC Wainwright Issues Optimistic Outlook for AVDL EarningsSeptember 9, 2025 | americanbankingnews.comAvadel licenses valiloxybate in bid to expand sleep disorder pipelineSeptember 8, 2025 | thepharmaletter.comTAvadel (AVDL) Licenses Valiloxybate and Unveils LUMRYZ Data at World Sleep 2025September 8, 2025 | finance.yahoo.comInvenomic Capital Management LP Purchases New Holdings in Avadel Pharmaceuticals PLC. $AVDLSeptember 8, 2025 | marketbeat.comHC Wainwright Raises Avadel Pharmaceuticals (NASDAQ:AVDL) Price Target to $36.00September 7, 2025 | marketbeat.comQ3 Earnings Forecast for AVDL Issued By Lifesci CapitalSeptember 7, 2025 | marketbeat.comRussell Investments Group Ltd. Cuts Stock Holdings in Avadel Pharmaceuticals PLC. $AVDLSeptember 7, 2025 | marketbeat.comAvadel Pharmaceuticals (NASDAQ:AVDL) Stock Price Expected to Rise, HC Wainwright Analyst SaysSeptember 7, 2025 | americanbankingnews.comQ2 Earnings Forecast for AVDL Issued By Lifesci CapitalSeptember 6, 2025 | marketbeat.comAvadel Pharmaceuticals (NASDAQ:AVDL) Raised to Hold at Wells Fargo & CompanySeptember 6, 2025 | marketbeat.comAvadel Pharmaceuticals (NASDAQ:AVDL) Rating Increased to Strong-Buy at Lifesci CapitalSeptember 6, 2025 | marketbeat.comOMERS ADMINISTRATION Corp Makes New $305,000 Investment in Avadel Pharmaceuticals PLC. $AVDLSeptember 6, 2025 | marketbeat.comAvadel Pharmaceuticals (NASDAQ:AVDL) Stock Rating Upgraded by Wells Fargo & CompanySeptember 6, 2025 | americanbankingnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAVDL, AMAG, ARCT, and ABUS Company DescriptionsArbutus Biopharma NASDAQ:ABUS$4.46 -0.44 (-8.98%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$4.44 -0.02 (-0.43%) As of 09/12/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.AMAG Pharmaceuticals NASDAQ:AMAGAMAG Pharmaceuticals, Inc., a pharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, and anemia management in the United States. The company markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and Vyleesi (bremelanotide), an auto-injector device for the treatment of hypoactive sexual desire disorder in pre-menopausal women. Its product candidates also include AMAG-423 (ovine), an antibody fragment, which is in Phase 2b/3a trial for the treatment of severe preeclampsia in pregnant women; and Ciraparantag, an anticoagulant reversal agent that is in planned Phase 2b trial for the treatment of novel oral anticoagulants or low molecular weight heparin. The company sells Feraheme to authorized wholesalers and specialty distributors. The company has license agreements with Endoceutics, Inc., Palatin Technologies, Inc., Velo Bio, LLC, Prasco, LLC, Perosphere Pharmaceuticals Inc., and Antares Pharma, Inc. AMAG Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.Arcturus Therapeutics NASDAQ:ARCT$17.32 -0.72 (-3.99%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$17.81 +0.49 (+2.83%) As of 06:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.Avadel Pharmaceuticals NASDAQ:AVDL$15.40 -0.46 (-2.90%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$15.15 -0.25 (-1.62%) As of 05:21 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Football Season Is Here and DraftKings Stock Is Surging RH Stock Slides After Mixed Earnings and Tariff Concerns Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
